MCL1 and B-cell chronic lymphocytic leukemia: In patient derived CLL cells, AT-7519 treatment displayed time-dependent cytotoxicity; induced apoptosis, irrespective of time and dose; inhibited pS2; reduced MCL-1 protein and mRNA; and induced PARP cleavage, in a dose-dependent manner [144].